ClinicalTrials.gg
RecruitingNCT07446153Updated Apr 3, 2026

A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

A Phase 1/2 interventional study of HRS-8364 Tablet in Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
282
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily joining this study, signing an form, good compliance, and able to cooperate with follow-up.
  2. Age range: 18-75 years old (including boundary values), both males and females are eligible.
  3. Monotherapy dose escalation stage: advanced solid tumors diagnosed by cytology or histology, which have failed standard treatment or are intolerant to previous standard treatment or have no standard treatment.
  4. Monotherapy dose expansion stage: advanced solid tumors diagnosed by cytology or histology; with other systemic treatments during the recurrence or stage, and disease progression during or after treatment; The combined dose expansion phase allows for the inclusion of individuals who have not received prior treatment with immuno (ICIs).
  5. Efficacy expansion of monotherapy: advanced solid tumors diagnosed by histopathology or cytology; with other systemic treatments during the recurrence or metastasis stage, and disease progression during or after treatment.
  6. At least one that meets the v1.1 criteria.
  7. PS score: 0 to 1.
  8. Expected survival ≥ 12 weeks.
  9. Female subjects with reproductive ability and male subjects with partners who are reproductive women must agree to use efficient during the trial period and within 30 days after the last dose of HRS-8364 (whichever comes later), have no fertility plan, and avoid donating eggs/sperm; Female subjects with fertility must have a negative blood pregnancy test within 7 days prior to the first administration and must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Untreated ; Or accompanied by meningeal , spinal cord compression, etc.
  2. Large blood vessels invasion confirmed by imaging, or the subject's tumor has a high possibility of invading important blood vessels and causing fatal bleeding during treatment judged by researchers.
  3. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion accompanied by clinical symptoms.
  4. Severe bone damage caused by tumor bone metastasis, including uncontrolled severe bone pain, pathological fractures in important areas that have occurred or are expected to occur in the past 6 months, and spinal cord compression. Subjects who require analgesic medication must have a stable analgesic treatment plan in place at the time of entry into the study.
  5. Other malignant tumors in the past 5 years or at the same time.
  6. Major arterial/venous thrombotic events within 6 months prior to the first use of medication, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction (excluding asymptomatic lacunar cerebral infarction)), deep vein thrombosis (excluding asymptomatic and non anticoagulant intramuscular vein thrombosis), and pulmonary embolism.
  7. Past or current active interstitial lung disease requiring treatment, non-infectious pneumonia requiring systemic therapy (such as radiation pneumonitis); Currently, individuals with active pneumonia or confirmed severe pulmonary ventilation dysfunction through lung function tests.
  8. Individuals with active pulmonary tuberculosis. Individuals who have undergone sufficient treatment and have stopped anti tuberculosis treatment for at least 3 months prior to their first medication can be enrolled in the study.
  9. Known to have a positive history of (HIV) or acquired immunodeficiency syndrome (AIDS). Known to have active viral hepatitis.
  10. Unable to swallow pills normally or experiencing gastrointestinal dysfunction, which may affect drug absorption according to researchers' assessment.
  11. Individuals who have experienced intestinal obstruction or gastrointestinal perforation within 3 months prior to their first medication use.
  12. According to the researchers' assessment, there are other factors that may affect the research results or lead to the forced termination of this study, such as alcohol abuse, drug use, drug abuse, other serious illnesses (including mental illnesses) that require concurrent treatment, serious laboratory test abnormalities, and family or social factors that may affect medication safety.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    HRS-8364 Group

    HRS-8364 in different doses.

    Drug: HRS-8364 Tablet

Interventions

  • DrugHRS-8364 Tablet

    HRS-8364 tablet.

06

What researchers measure

Primary outcomes

  1. The Dose-Limiting Toxicity (DLT)

    Time frame: Post-dose at Day 1 to Day 21.

  2. The Maximum Tolerated Dose (MTD)

    Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.

  3. Recommended dosage for Phase II (RP2D)

    Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.

  4. Incidence and severity of adverse events (AEs)

    Time frame: From signing the informed consent form to safety follow-up completed, about 1 year.

  5. Objective Response Rate (ORR)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

Secondary outcomes

  1. Maximum Concentration of HRS-8364 (Cmax)

    Time frame: Day 1 pre-dose to the end of treatment visit, about 1 year.

  2. Time to maximum plasma concentration (Tmax)

    Time frame: Day 1 pre-dose to the end of treatment visit, about 1 year.

  3. Area under the concentration versus time curve of HRS-8364 from time zero to time t (AUC0-t).

    Time frame: Day 1 pre-dose to the end of treatment visit, about 1 year.

  4. Bioaccumulation of HRS-8364 in postprandial relative fasting state.

    Time frame: Cycle 0 Day1 pre-dose to Cycle 1 Day 3, about 6 days.

  5. Duration of relief (DOR).

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  6. Disease Control Rate (DCR).

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  7. Progression-free survival (PFS).

    Time frame: From the first administration to the end of treatment visit, about 1 year.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07446153
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 19, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Apr 3, 2026

Study contacts

Cong Wen
Contact
cong.wen@hengrui.com
+86-021-61053363
Weixia Li
Contact
weixia.li@hengrui.com
+86-021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion